You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
上海萊士(002252.SZ):SR604注射液進入Ⅱb期臨牀試驗研究

格隆匯7月8日丨上海萊士(002252.SZ)公佈,公司於近日在國家藥品監督管理局藥物臨牀試驗登記與信息公示平臺公示了IIb期臨牀試驗登記信息。SR604注射液是一種人源化高親和力結合人活化蛋白C,特異性抑制人活化蛋白C抗凝血功能的單克隆抗體制劑。

SR604注射液擬用於血友病A/B及先天性凝血因子Ⅶ缺乏症患者出血的預防治療。目前國內外血友病常規預防治療是每週2-3次靜脈注射血源或重組凝血因子。SR604通過皮下注射給藥,預防治療改善出血,目前已完成PartA劑量遞增Ⅰ期試驗(單次給藥階段)共6個劑量組的受試者入組、用藥,分別爲0.025mg/kg、0.05mg/kg、0.1mg/kg、0.2mg/kg、0.4mg/kg、0.8mg/kg;以及PartB療效探索Ⅱa期試驗(多次給藥階段)共2個劑量組:0.05mg/kg和0.1mg/kg,每2周給藥一次共6個月的受試者入組。已有的安全性和初步有效性數據支持開展PartC療效探索Ⅱb期試驗(多次給藥階段),將開展0.4mg/kg劑量組每4、6、8周給藥一次共6個月的3組用藥間隔試驗。該品種研製成功,有望顯著改善血友病患者的用藥體驗。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account